Viewpoint Capital Management LLC Sells 247 Shares of Johnson & Johnson (NYSE:JNJ)

Viewpoint Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,749 shares of the company’s stock after selling 247 shares during the period. Johnson & Johnson accounts for approximately 1.1% of Viewpoint Capital Management LLC’s investment portfolio, making the stock its 24th biggest holding. Viewpoint Capital Management LLC’s holdings in Johnson & Johnson were worth $1,863,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson during the 1st quarter worth $31,000. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $44,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $43,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in shares of Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Cowen decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, August 5th. Finally, The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.86 on Friday. The stock’s 50-day moving average is $155.68 and its 200-day moving average is $153.49. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $165.98. The stock has a market cap of $399.26 billion, a P/E ratio of 10.34, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.